Stocktoria
Organon & Co. OGN
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2021-05-14
Chart by TradingView
5/9
Piotroski F — financial health
—
Altman Z″ — distress risk
47.1%
Dividend payout · moderate
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $6.2B | $6.4B | $6.3B | $6.2B | $6.3B |
| Gross profit | $3.3B | $3.7B | $3.7B | $3.9B | — |
| Net income | $187.0M | $864.0M | $1.0B | $917.0M | $1.4B |
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M | $2.2B |
| Free cash flow | $538.0M | $764.0M | $548.0M | $662.0M | $2.0B |
| Total assets | $12.9B | $13.1B | $12.1B | $11.0B | $10.7B |
| Total liabilities | $12.1B | $12.6B | $12.1B | $11.8B | — |
| Shareholders' equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.5B |
| Ratios | |||||
| Gross margin | 53.3% | 58.0% | 59.8% | 62.8% | — |
| Net margin | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% |
| FCF margin | 8.7% | 11.9% | 8.7% | 10.7% | 31.2% |
| Return on assets | 1.5% | 6.6% | 8.5% | 8.4% | 12.6% |
| Return on equity | 24.9% | 183.1% | -1461.4% | -102.8% | -89.6% |
| Debt / equity | 11.47× | 18.81× | -125.14× | -9.98× | -6.05× |
| Current ratio | 1.82 | 1.60 | 1.54 | 1.56 | 1.45 |
| Revenue growth | -2.9% | 2.2% | 1.4% | -2.1% | -3.5% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Bridgewater Associates, LP | 594,483 | $3.6M |
| Point72 Asset Management, L.P. | 238,000 | $1.4M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001821825 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.